New preclinical findings support the antifibrotic potential of engineered macrophages in several fibrosis models.
Engineered TIM4-expressing macrophages correct defective efferocytosis in MASH, exhibiting potent antifibrotic activity.
Liver fibrosis is a central pathway in many liver diseases, including MASH, acute liver injury, primary sclerosing cholangitis, primary biliary cholangitis, and others. Treatment options for patients with advanced liver disease are limited. Liver disease is characterized by defective efferocytosis (an inflammatory process by which macrophages clear dead hepatocytes), activation of hepatic stellate cells leading to collagen deposition, and chronic inflammation.
New clinical findings show that macrophages can be genetically engineered to target specific key pathways underlying liver disease, including TIM4 (restores efferocytosis), relaxin (hepatic stellate cell activation ), and IL10 (reduces inflammation). Specifically, a dose of TIM4-expressing macrophages, alone or in combination with relaxin, induced liver fibrosis in the translationally relevant choline-deficient, L-amino acid-dependent, high-fat diet (CDAHFD) MASH model. Significantly reduces hepatic stellate cell activation. Engineered macrophages were well tolerated and outperformed non-engineered cells in all models.
“We are pleased to present promising preclinical data supporting the therapeutic potential of our engineered macrophages to address an important unmet need in liver fibrosis, which occurs in advanced stages of MASH. has been.”
Charisma expects to nominate a development candidate for its liver fibrosis program in the first quarter of 2025.
The poster presented at AASLD 2024 is now available online in the “Publications” section of Charisma’s website https://carismatx.com/technology/publications/
About Charisma Therapy
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on using our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies for the treatment of cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a critical role in both innate and adaptive immune responses. Karishma is at the headquarters.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including anticipated discovery, preclinical and clinical development activities for Charisma’s product candidates, but Not limited to them. Safety, efficacy, benefits and identifiable market for Charisma’s product candidates, and clinical trial results for Charisma’s product candidates. All statements other than statements of historical fact are statements that may be considered forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “should,” “could,” “likely,” ” plans,” “continue,” “will,” “schedule,” and “will” and similar expressions are intended to indicate forward-looking statements, although all forward-looking statements These are not identifying words. These forward-looking statements are predictions based on the Company’s current expectations and estimates about future events and various assumptions. Although Charisma believes that expectations reflected in forward-looking statements are reasonable, Charisma cannot guarantee future events, results, actions, activity levels, performance or achievements, and biotechnology development and potential regulatory approvals. The timing and results are inherently uncertain. Forward-looking statements are subject to risks and uncertainties that could cause Charisma’s actual operations or results to differ materially from those expressed in any forward-looking statements, including risks and uncertainties of Charisma’s own. Our ability to advance product candidates, potential regulatory designations related to receipt and timing, approval and commercialization of product candidates, our ability to enroll clinical trial sites and eligible patients, our supply chain and manufacturing facilities, Karisma’s product candidates To Ability to retain and recognize the benefits of certain positions received, timing and results of clinical trials, Charisma’s ability to fund development activities and achieve development goals, Charisma’s ability to protect intellectual property, and others Risks and uncertainties are described under the heading “Risk Factors” in Charisma’s Annual Report on Form 10-K for the year ended.
Investors:
investors@carismatx.com
Media Contact:
jstern@realchemistry.com
